# ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06498479/  
OnCo record `nct06498479` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HS-20093 in non-small-cell lung cancer, now recruiting.

## Summary

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06498479, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: ARTEMIS-008：A Multicenter, Randomised, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy. Planned enrolment is 460 participants (estimated). The study started in 2024-07-04 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: ARTEMIS-008
- Tags: ctgov-ingest
- Registry id: NCT06498479
- Phase: 3
- Setting: ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
- Sponsor: Hansoh BioMedical R&D
- Enrolled: 460

## Sources

- ClinicalTrials.gov NCT06498479: https://clinicaltrials.gov/study/NCT06498479

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [HS-20093](https://onco.cc/drugs/hs-20093/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06498479.json